Oncotelic Therapeutics, Inc. 8-K

What Happened
On April 16, 2026, Oncotelic Therapeutics, Inc. (OTLC) filed a Current Report on Form 8-K (Item 8.01) to announce its annual results and corporate updates. The company issued a press release summarizing those results and updates; that press release is furnished as Exhibit 99.1 to the 8-K.

Key Details

• Filing date: April 16, 2026 (Form 8-K, Item 8.01 — Other Events).
• Disclosure format: Press release announcing annual results and corporate updates attached as Exhibit 99.1.
• No additional financial statements or schedules were furnished with this 8-K beyond the press release.

Why It Matters
The press release is the company’s formal public update on its annual performance and corporate developments; investors should review Exhibit 99.1 for the specific financial figures, operational highlights, and any management or strategy changes. Because the 8-K itself does not include detailed financial schedules beyond the press release, retail investors seeking numbers on revenue, earnings, or material corporate actions should read the attached release and monitor subsequent SEC filings for any follow-up disclosures.